Page 158 - 2021_07-Haematologica-web

M.D. Berger et al.
of chemotherapy) is given just to PET-positive sites after four cycles of chemotherapy. According to an interim analysis, this can compensate the inferior outcome of this population.37 Furthermore, the authors of this trial com- municated that radiotherapy to PET-negative bulky dis- ease is not needed.38
In the latest ESMO guidelines, consolidation radiother- apy for DLBCL patients is recommended for both elderly and intermediate- and high-risk young patients with bulky disease.6 NCCN is less firm, and mainly restricts its recommendation to residual disease (partial remission or PET-positivity, Online Supplementary Table S1). These rec-
Figure 3. Effect of consolidation radiotherapy on overall survival. Circles are proportional to trial size i.e., number of patients; retracted trials are displayed with hollow circles. CI: Confidence Interval.
Figure 4. Time trend plot on the effect of consolidation radiotherapy. Circles are proportional to weight in analysis; dashed line shows the fitted linear regression; retracted trials are in grey. ln: natural logarithm.
1928
haematologica | 2021; 106(7)